NASDAQ · PLRX
Healthcare · Biotechnology
$1.17
Up+$0.04 (+3.54%)
Updated Sep 12, 2026, 5:20 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PLRX closed at $1.17 after 20 trading sessions, up 9.35% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $1.14 | $1.18 | $1.14 | $1.17 | 173.46K |
| Sep 10, 2026 | $1.13 | $1.16 | $1.13 | $1.13 | 299.4K |
| Sep 9, 2026 | $1.12 | $1.17 | $1.12 | $1.15 | 450.17K |
| Sep 8, 2026 | $1.11 | $1.175 | $1.11 | $1.135 | 682.89K |
| Sep 4, 2026 | $1.12 | $1.185 | $1.11 | $1.16 | 559.9K |
| Sep 3, 2026 | $1.15 | $1.17 | $1.13 | $1.13 | 299.29K |
| Sep 2, 2026 | $1.11 | $1.17 | $1.11 | $1.16 | 740.06K |
| Sep 1, 2026 | $1.11 | $1.128 | $1.10 | $1.11 | 267.48K |
| Aug 31, 2026 | $1.10 | $1.12 | $1.0932 | $1.10 | 400.01K |
| Aug 28, 2026 | $1.15 | $1.15 | $1.11 | $1.11 | 233.14K |
| Aug 27, 2026 | $1.16 | $1.16 | $1.14 | $1.15 | 112.83K |
| Aug 26, 2026 | $1.19 | $1.19 | $1.15 | $1.16 | 135.09K |
| Aug 25, 2026 | $1.14 | $1.20 | $1.13 | $1.19 | 321.95K |
| Aug 24, 2026 | $1.14 | $1.15 | $1.12 | $1.14 | 316.09K |
| Aug 21, 2026 | $1.12 | $1.17 | $1.12 | $1.155 | 504.69K |
| Aug 20, 2026 | $1.188 | $1.188 | $1.12 | $1.12 | 401.77K |
| Aug 19, 2026 | $1.17 | $1.20 | $1.16 | $1.17 | 681.75K |
| Aug 18, 2026 | $1.17 | $1.23 | $1.12 | $1.15 | 1.37M |
| Aug 17, 2026 | $1.07 | $1.12 | $1.07 | $1.10 | 590.77K |
| Aug 14, 2026 | $1.09 | $1.09 | $1.06 | $1.07 | 235.03K |
The latest Smart Investors Daily articles mentioning PLRX.
PLRX research
Company profile and research snapshot.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 13, 2026 | Canaccord Genuity | Hold | — |
| Mar 12, 2026 | Piper Sandler | Overweight | — |
| Nov 7, 2025 | RBC Capital | Sector Perform | — |
| Oct 10, 2025 | JP Morgan | Underweight | — |
| Aug 8, 2025 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 18, 2026
Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8
Benzinga · Aug 11, 2026
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 49.3 percent increase over losses of $(0.71) per share
Yahoo · Jul 13, 2026
Appointments bring global oncology drug development experience and deepen Board’s operational and regulatory expertise SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointments of Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to its Board of Directors. "On behalf of the Board of Directors, I am
SeekingAlpha · Feb 24, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PLRX.
